No Data
CSPC Pharmaceutical Group Limited-B (02509.HK): China Securities Regulatory Commission accepted the company's H股全流通计划申请.
Great Wall News October 28th, Quansin Biotech-B (02509.HK) announced that the China Securities Regulatory Commission has recently accepted the company's shareholders' suggestions to implement the application for full circulation of H shares. According to the relevant application documents, the company has applied to convert 17,322,400 shares held by certain shareholders into H shares and list them on the Hong Kong Stock Exchange, accounting for approximately 7.80% of the company's total issued share capital as of the announcement date. After the full circulation of H shares, all domestic shareholders participating in the full circulation of H shares will still need to comply with the share lock-up requirements under the Hong Kong Stock Exchange listing rules and applicable laws and regulations.
Hong Kong stock abnormal | Chang Xin Biology-B (02509) rose more than 7%, achieving revenue of 44.919 million yuan in the first half of the year. Previously reached a cooperation with huadong medicine.
China Good Biotech-B (02509) rose more than 7%, as of the time of publication, it increased by 7.54%, closing at 24.95 Hong Kong dollars.
QYUNS-B: 2024 INTERIM REPORT
Does Qyuns Therapeutics (HKG:2509) Have A Healthy Balance Sheet?
CICC: Maintains a "outperform" rating for Hansoh Pharma, with a target price raised to HK$21.12.
CICC released a research report stating that due to the increased down payment for cooperation and the thickening of performance, it raised the profit forecast for Hansoh Pharma (03692) in 2024 by 30.5% to 4.472 billion yuan, and raised the profit forecast for 2025 by 17.8% to 4.19 billion yuan. It maintains an "outperform industry" rating. Based on the SOTP valuation method, considering the upward revision of profit forecast and the temporary pressure on the company's generic drug sector, the target price is raised by 18.6% to 21.12 Hong Kong dollars. The company's current revenue is 6.506 billion yuan, a year-on-year increase of 44.2%; the net income attributable to the mother is 2.726 billion yuan, a year-on-year increase of 111.5%, and the performance is higher than the bank's expectations.
Qyuns Therapeutics Shrinks Loss in H1
No Data
No Data